We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committees to Consider Link Between Lou Gehrig’s Disease and Statins
FDA Advisory Committees to Consider Link Between Lou Gehrig’s Disease and Statins
December 11, 2007
Although much of the attention during the joint Nonprescription Drugs and Endocrinologic and Metabolic Drugs advisory committee meeting scheduled for Dec. 13 will pertain to Merck’s OTC-switch application for its statin Mevacor (see story), the committee likely will be asked to weigh in on a potential link between the use of statins and Lou Gehrig’s disease.